The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.
The information on this site is intended for healthcare professionals in the United States and is not intended for the general public.
|
||
 |
||
In March 1991, Merck, which had prided itself in the past for maintaining good community relations, and learning a lesson from the trouble other manufacturers had encountered, made the unusual move of forming a community advisory board. The board would advise Merck in designing clinical trials, setting up a compassionate use program to provide CRIXIVAN to the sickest patients, and lobbying the government and the FDA to usher potential treatments through the approval process more quickly. Even without a drug ready for testing, Merck had opened up the channels of communication.
